What is talquetamab-tgvs?

Talquetamab(talquetamab-tgvs)is the first bispecificGPRC5DdirectedCD3 Tcell engager, indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior treatment regimens, including proteasome inhibitors, immunomodulators and anti-CD38monoclonal antibodies. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and characterization of clinical benefit in confirmatory trials. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.